Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
Wu, Yi-Long (Guangdong Lung Cancer Institute)
John, Thomas (Austin Health)
Grohe, Christian (Evangelische Lungenklinik)
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Goldman, Jonathan W. (University of California)
Kim, Sang-We (University of Ulsan)
Kato, Terufumi (Kanagawa Cancer Center)
Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology)
Vu, Huu Vinh (Choray Hospital)
Wang, Zhije (Chinese Academy of Medical Sciences)
Lu, Shun (Shanghai Jiao Tong University)
Lee, Kye Young (Konkuk University Medical Center)
Akewanlop, Charuwan (Siriraj Hospital)
Yu, Chong-Jen (National Taiwan University College of Medicine)
de Marinis, Filippo (European Institute of Oncology)
Bonanno, Laura (Istituto Oncologico Veneto)
Domine, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Shepherd, Frances A. (University of Toronto)
Zeng, Lingmin (AstraZeneca)
Atasoy, Ajlan (AstraZeneca)
Herbst, Roy S. (Yale School of Medicine)
Tsuboi, Masahiro (National Cancer Center Hospital East)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. Here, we report prespecified and exploratory analyses of adjuvant chemotherapy use and outcomes from ADAURA. Methods: Patients with resected stages IB to IIIA EGFRm NSCLC were randomized 1:1 to receive osimertinib or placebo for 3 years. Adjuvant chemotherapy before randomization was not mandatory, per physician and patient choice. DFS in the overall population (IB-IIIA), with and without adjuvant chemotherapy, was a prespecified analysis. Exploratory analyses included the following: adjuvant chemotherapy use by patient age, disease stage, and geographic location; DFS by adjuvant chemotherapy use and disease stage. Results: Overall, 410 of 682 patients (60%) received adjuvant chemotherapy (osimertinib, n = 203; placebo, n = 207) for a median duration of 4. 0 cycles. Adjuvant chemotherapy use was more frequent in patients: aged less than 70 years (338 of 509; 66%) versus more than or equal to 70 years (72 of 173; 42%); with stages II to IIIA (352 of 466; 76%) versus stage IB (57 of 216; 26%); and enrolled in Asia (268 of 414; 65%) versus outside of Asia (142 of 268; 53%). A DFS benefit favoring osimertinib versus placebo was observed in patients with (DFS hazard ratio = 0. 16, 95% confidence interval: 0. 10-0. 26) and without adjuvant chemotherapy (hazard ratio = 0. 23, 95% confidence interval: 0. 13-0. 40), regardless of disease stage. Conclusions: These findings support adjuvant osimertinib as an effective treatment for patients with stages IB to IIIA EGFRm NSCLC after resection, with or without previous adjuvant chemotherapy.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adjuvant chemotherapy ; EGFR ; EGFR-TKI ; NSCLC ; Osimertinib
Publicat a:	Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433, ISSN 1556-1380

DOI: 10.1016/j.jtho.2021.10.014
PMID: 34740861

11 p, 379.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats